Welcome to Nanjing BioPoint Diagnostic Technology
English | 中文简体

Nanjing BioPoint

 

Nanjing BioPoint Diagnostic Technology Co. Ltd (Nanjing BioPoint) is a high tech. medical diagnostic product company supported by the Nanjing 321 government funding scheme. The company is located within the JiangSu Life Science and Technology Innovation Park, close to the city of Nanjing, China. The founder Prof. David Anderson is the deputy director, head of the diagnostic product development laboratory and head of the research innovation and development office of the Burnet Medical Research Institute in Melbourne, Australia.  He has published more than 60 papers in diagnostic methods, vaccine research and development and is the inventor of 9 patent families.  His commercial research projects have recently won award as one of the “Ten of the best” projects for 2010 from the National Health and Medical Research Council, Australia, and the Australian Pharmaceutical “Prime Award” for life science innovation.
 
The mission of the Nanjing BioPoint is to commercialise the point of care diagnostic product, either recently developed by the Burnet Institute, or currently under development by the company itself.  The first product is the test of the level of enzyme alanine aminotransferase (ALT) in blood.  The level of ALT in blood is an important indicator for liver function.  People suffer from the hepatitis B and hepatitis C, and the tuberculosis patients and HIV carriers undergoing drug treatment who suffer from liver damage because of drug toxicity, as well as the non-alcoholic fatty liver (steatosis) and alcoholic induced cirrhosis sufferers all have elevated blood ALT level.  Current test methods have stringent requirements for measurement conditions, especially in temperature control.  It, therefore, has restricted the test to be performed only in hospitals and laboratories with expensive equipments to satisfy required conditions.  This causes great inconveniences to many patients living in Africa, India and some Southeast Asian counties.  The result is many who needs to be tested in those countries and regions do not have access to the necessary test.
 
The number of liver function tests needs to be carried out in the world is very large: there are 550 million hepatitis B and C suffers (more than 130 million of them living in China), 130 million tuberculosis patients and HIV carriers undertook drug treatment, more than 100 million non-alcoholic fatty liver (steatosis) suffers living in developed countries as such Australian and the United States of America.  Many traditional Chinese medicines could also cause liver damages.  All these patients need to have at least twice a year testing of liver function for the rest of their lives.  The total number of liver function test required per year exceeds 1.5 billion worldwide. Because the limitation of current technology, a great proportion of the testing need cannot be satisfied.
 
The liver function point of care product developed by the Nanjing BioPoint eliminated the requirement for temperature remains constant during measurement.  Using a small amount of finger blood, it can reliably test whether the level of ALT in a patient’s blood is high enough to warrant medical intervention.  The results can be read by naked eyes and the entire test only takes several tens of minutes.  The procedure is very simple and can be performed by paramedical with short training. This enables the test to be carried out in Africa, certain Southeast Asian countries, India and other countries and regions where there are not adequate hospital and laboratory facilities.  Because the test process is simple, the results reliable and the cost per test is low, this product is especially suitable for the public health projects strongly supported by the international aid agencies (eg. WHO,  Bill Gates Foundation,  MSF, etc.).  The CD4 T cell test used for AIDS patient, which is invented by the founder of the Nanjing BioPoint Prof. David Anderson and based on the same principles, has already been successfully commercialized and endorsed by the World Health Organisation.
 
Using the ALT point of care diagnostic product as a foundation stone, the Nanjing BioPoint will develop a series of point of care diagnostic products, including test for tuberculosis, test for various type of hepatitis and the test for the amount of virus in blood etc. in the future.